Literature DB >> 21320089

Allergy to low dose sugammadex.

L Menéndez-Ozcoidi1, J R Ortiz-Gómez, J M Olaguibel-Ribero, M J Salvador-Bravo.   

Abstract

We describe the case of a fit 17-year-old man who developed a severe allergic reaction to a low clinical dose of sugammadex (3.2 mg kg(-1) , 200 mg intravenously), 1 min after its administration. This was manifest by an intense erythema over the anterior part of the thorax, severe lip and palpebral oedema and bilateral wheeze. On later investigation, the patient had a positive skin prick test to sugammadex (5-mm diameter response, with a negative saline control and positive histamine control of 5 mm) and no response to any other drug tested. Other diagnostic tests supported a diagnosis of allergic reaction to sugammadex.
© 2011 The Authors. Anaesthesia © 2011 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320089     DOI: 10.1111/j.1365-2044.2010.06611.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  12 in total

1.  Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery.

Authors:  Milan Adamus; Lumir Hrabalek; Tomas Wanek; Tomas Gabrhelik; Jana Zapletalova
Journal:  J Anesth       Date:  2011-08-13       Impact factor: 2.078

2.  Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

Authors:  Friederike Haerter; Jeroen Cedric Peter Simons; Urs Foerster; Ingrid Moreno Duarte; Daniel Diaz-Gil; Shweta Ganapati; Katharina Eikermann-Haerter; Cenk Ayata; Ben Zhang; Manfred Blobner; Lyle Isaacs; Matthias Eikermann
Journal:  Anesthesiology       Date:  2015-12       Impact factor: 7.892

3.  Three suspected cases of sugammadex-induced anaphylactic shock.

Authors:  Tomonori Takazawa; Yukinari Tomita; Nagahide Yoshida; Akihiro Tomioka; Tatsuo Horiuchi; Chie Nagata; Masaki Orihara; Makiko Hardy Yamada; Shigeru Saito
Journal:  BMC Anesthesiol       Date:  2014-10-17       Impact factor: 2.217

4.  Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.

Authors:  Xinmin Wu; Helle Oerding; Jin Liu; Bernard Vanacker; Shanglong Yao; Vegard Dahl; Lize Xiong; Casper Claudius; Yun Yue; Yuguang Huang; Esther Abels; Henk Rietbergen; Tiffany Woo
Journal:  BMC Anesthesiol       Date:  2014-07-12       Impact factor: 2.217

Review 5.  Preparing for the unexpected: special considerations and complications after sugammadex administration.

Authors:  Hajime Iwasaki; J Ross Renew; Takayuki Kunisawa; Sorin J Brull
Journal:  BMC Anesthesiol       Date:  2017-10-17       Impact factor: 2.217

6.  Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-κB and Nrf2/HO-1 pathways.

Authors:  Jing Ye; Hongmei Piao; Jingzhi Jiang; Guangyu Jin; Mingyu Zheng; Jinshi Yang; Xiang Jin; Tianyi Sun; Yun Ho Choi; Liangchang Li; Guanghai Yan
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

7.  A suspected case of rocuronium-sugammadex complex-induced anaphylactic shock after cesarean section.

Authors:  Masakazu Yamaoka; Miki Deguchi; Kiichiro Ninomiya; Toshiaki Kurasako; Mutsuko Matsumoto
Journal:  J Anesth       Date:  2016-11-16       Impact factor: 2.078

8.  In the hour of Sugammadex.

Authors:  Jin Young Chon
Journal:  Korean J Anesthesiol       Date:  2013-01-21

9.  The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade.

Authors:  Soon Ho Cheong; Seunghee Ki; Jiyong Lee; Jeong Han Lee; Myoung-Hun Kim; Dongki Hur; Kwangrae Cho; Se Hun Lim; Kun Moo Lee; Young-Jae Kim; Wonjin Lee
Journal:  Korean J Anesthesiol       Date:  2015-11-25

Review 10.  Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Authors:  Stefan Josef Schaller; Heidrun Fink
Journal:  Core Evid       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.